References
- National Audit Office. Reducing Brain Damage: Faster Access to Better Stroke Care. The Stationary Office, London, UK (2005).
- Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin. Rehabil.16(5), 515–522 (2002).
- Sommerfeld DK, Eek EUB, Svensson A-K, Holmqvist LW, von Arbin MH. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke35(1), 134–139 (2004).
- Lance JW. Symposium synopsis. In: Spasticity: Disordered Motor Control. Feldman RG, Young RR, Koella WP (Eds). Symposium Specialists Inc, Chicago, IL, USA (1980).
- Pandyan AD, Gregoric M, Barnes MP et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil. Rehabil.27(1–2), 2–6 (2005).
- Royal College of Physicians, British Society of Rehabiliation Medicine, Chartered Society of Physiotherapy and Association of Chartered Physiotherapists Interested in Neurology. Spasticity in Adults: Management Using Botulinum Toxin. National Guidelines. Royal College of Physicians, London, UK (2009).
- Mayer NH, Esquenazi A, Childers MK. Common patterns of clinical motor dysfunction. Muscle Nerve20(Suppl. 6), S21–S35 (1997).
- Sheean GL. Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr. Opin. Neurol.14(6), 771–776 (2001).
- Ada L, O’Dwyer N, O’Neill E. Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study. Disabil. Rehabil.28(13–14), 891–897 (2006).
- Leonard CT, Gardipee KA, Koontz JR, Anderson J-H, Wilkins SA. Correlation between impairment and motor performance during reaching tasks in subjects with spastic hemiparesis. J. Rehabil. Med.38(4), 243–249 (2006).
- Sheean DG. Is spasticity painful? Eur. J. Neurol.16(2), 157–158 (2009).
- Barnes MP. Management of spasticity. Age Ageing27(2), 239–245 (1998).
- Intercollegiate Stroke Working Party. National Clinical Guideline for Stroke (Third Edition). Royal College of Physicians, London, UK (2008).
- Collins MD, East AK. Phylogeny and taxonomy of the food-borne pathogen Clostridium botulinum and its neurotoxins. J. Appl. Microbiol.84(1), 5–17 (1998).
- Goonetilleke A, Harris JB. Clostridial neurotoxins. J. Neurol. Neurosurg. Psychiatry75(Suppl. 3), 35–39 (2004).
- Sobel J. Botulism. Clin. Infect. Dis.41(8), 1167–1173 (2005).
- Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J. Neural Transm.115(4), 559–565 (2008).
- Rossetto O, Montecucco C. How botulinum toxins work. In: Handbook of Botulinum Toxin Treatment (Second Edition). Moore P, Naumann M (Eds). Blackwell Science Ltd, Oxford, UK (2003).
- Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur. J. Neurol.13(Suppl. 4), 1–9 (2006).
- Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action. Arq. Neuropsiquiatr.63(1), 180–185 (2005).
- Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil. Rehabil.29(23), 1761–1768 (2007).
- Singh BR. Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting. Neurotox. Res.9(2–3), 73–92 (2006).
- Ko C-P. Do nerve terminal sprouts contribute to functional recovery from botulinum neurotoxin A? J. Physiol.586(13), 3021 (2008).
- Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology26(5), 785–793 (2005).
- Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur. J. Neurol.13(Suppl. 1), 2–10 (2006).
- Pickett A. Dysport: pharmacological properties and factors that influence toxin action. Toxicon54(5), 683–689 (2009).
- Schroeder AS, Berweck S, Lee SH, Heinen F. Botulinum toxin treatment of children with cerebral palsy – a short review of different injection techniques. Neurotox. Res.9(2–3), 189–196 (2006).
- Das TK, Park DM. Effect of treatment with botulinum toxin on spasticity. Postgrad. Med. J.65(762), 208–210 (1989).
- Simpson DM, Alexander DN, O’Brien CF et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology46(5), 1306–1310 (1996).
- Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin. Rehabil.12(5), 381–388 (1998).
- Smith SJ, Ellis E, White S, Moore AP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin. Rehabil.14(1), 5–13 (2000).
- Bakheit AM, Thilmann AF, Ward AB et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke31(10), 2402–2406 (2000).
- Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J. Neurol. Neurosurg. Psychiatry69(2), 217–221 (2000); Erratum in J. Neurol. Neurosurg. Psychiatry70(6), 821 (2001).
- Bakheit AM, Pittock S, Moore AP et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur. J. Neurol.8(6), 559–565 (2001).
- Brashear A, Gordon MF, Elovic E et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N. Engl. J. Med.347(6), 395–400 (2002).
- Childers MK, Brashear A, Jozefczyk P et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch. Phys. Med. Rehabil.85(7), 1063–1069 (2004).
- Suputtitada A, Suwanwela NC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil. Rehabil.27(4), 176–184 (2005).
- Yelnik AP, Colle FM, Bonan IV, Vicaut E. Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin A. J. Neurol. Neurosurg. Psychiatry78(8), 845–848 (2007).
- Marco E, Duarte E, Vila J et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. J. Rehabil. Med.39(6), 440–447 (2007).
- Kong K-H, Neo J-J, Chua KS. A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity. Clin. Rehabil.21(1), 28–35 (2007).
- Jahangir AW, Tan HJ, Norlinah MI et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. Med. J. Malaysia62(4), 319–322 (2007).
- de Boer KS, Arwert HJ, de Groot JH, Meskers CGM, Mishre ADR, Arendzen JH. Shoulder pain and external rotation in spastic hemiplegia do not improve by injection of botulinum toxin A into the subscapular muscle. J. Neurol. Neurosurg. Psychiatry79(5), 581–583 (2008).
- McCrory P, Turner-Stokes L, Baguley IJ et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J. Rehabil. Med.41(7), 536–544 (2009).
- Brashear A, McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch. Phys. Med. Rehabil.85(5), 705–709 (2004).
- van Kuijk AA, Geurts ACH, Bevaart BJW, van Limbeek J. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature. J. Rehabil. Med.34(2), 51–61 (2002).
- Cardoso E, Rodrigues B, Lucena R, Oliveira IR, Pedreira G, Melo A. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arq. Neuropsiquiatr.63(1), 30–33 (2005).
- Garces K, McCormick A, McGahan L, Skidmore B. Botulinum toxin A for upper and lower limb spasticity: a systematic review. Technology report no 51. Canadian Coordinating Office for Health Technology Assessment, Ottawa, Canada (2005).
- Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J. Neural Transm.115(4), 617–623 (2008).
- Elia A, Filippini G, Calandrella D, Albanese A. Botulinum neurotoxins for post stroke spasticity in adults: a systematic review. Mov. Disord.24(6), 801–812 (2009).
- Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practioner192, 540–542 (1964).
- Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys. Ther.67(2), 206–207 (1987).
- Johnson GR. Measurement of spasticity. In: Upper Motor Neurone Syndrome and Spasticity (First Edition). Barnes MP, Johnson GR (Eds). Cambridge University Press, Cambridge, UK (2001).
- Burridge JH, Wood DE, Hermens HJ et al. Theoretical and methodological considerations in the measurement of spasticity. Disabil. Rehabil.27(1–2), 69–80 (2005).
- Wood DE, Burridge JH, van Wijck FM et al. Biomechanical approaches applied to the lower and upper limb for the measurement of spasticity: a systematic review of the literature. Disabil. Rehabil.27(1–2), 19–32 (2005).
- Voerman GE, Gregoric M, Hermens HJ. Neurophysiological methods for the assessment of spasticity: the Hoffmann reflex, the tendon reflex, and the stretch reflex. Disabil. Rehabil.27(1–2), 33–68 (2005).
- Naumann M, Albanese A, Heinen F, Molenaers G, Relja M. Safety and efficacy of botulinum toxin type A following long-term use. Eur. J. Neurol.13(Suppl. 4), 35–40 (2006).
- Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl.6, S146–S168 (1997).
- Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur. J. Neurol.13(Suppl. 1), 11–15 (2006).
- Moore P, Naumann M. General and clinical aspects of treatment with botulinum toxin. In: Handbook of Botulinum Toxin Treatment (Second Edition). Moore P, Naumann M (Eds). Blackwell Science Ltd, Oxford, UK (2003).
- Rodgers H, Shaw L, Price C et al. Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Trials9, 59 (2008).
- Shaw L, Rodgers H, Price C et al. BoTULS: a multi-centre randomised controlled trial to evaluate the clinical and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. Health Technology Assessment (In press).
Website
- Electronic Medicines Compendium www.emc.medicines.org.uk